Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Van Ingen v. Ha-Ngoc et al
Case Number:
1:14-cv-11672
Court:
Nature of Suit:
Multi Party Litigation:
Derivative Litigation
Judge:
Firms
-
August 26, 2016
Aveo Promises Reforms In Cancer Drug Derivative Settlement
Aveo Pharmaceuticals Inc.'s board has agreed to reform itself and the company's internal policies following an investor's derivative suit claiming it lied about the success of a clinical trial for a kidney cancer medication, according to a preliminary settlement submitted Thursday to a Massachusetts federal court.
-
April 29, 2015
Aveo Board Dumps Cancer Drug Derivative Suit
Board members at Aveo Pharmaceuticals Inc. dodged a derivative suit Tuesday when a Massachusetts federal judge ruled that the plaintiff didn't back her claims that the board was liable and should have taken her complaints about the company's kidney cancer drug tivozanib to them first.